Novartis [clinicaltrials_resource:7cb942c6d0724183a592d4221f454201]
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia [clinicaltrials:NCT00084071]Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients [clinicaltrials:NCT00098241]Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant [clinicaltrials:NCT00099736]Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant [clinicaltrials:NCT00099749]Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant [clinicaltrials:NCT00099801]Freedom Study: Myfortic in Kidney Transplant Patients [clinicaltrials:NCT00101738]Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302 [clinicaltrials:NCT00149864]clinicaltrials:NCT00149890Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients [clinicaltrials:NCT00149903]Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107 [clinicaltrials:NCT00149916]Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301 [clinicaltrials:NCT00149929]Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy [clinicaltrials:NCT00149942]Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife) [clinicaltrials:NCT00149968]Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients [clinicaltrials:NCT00149994]Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS) [clinicaltrials:NCT00150007]Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance [clinicaltrials:NCT00150020]Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion [clinicaltrials:NCT00150085]Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels [clinicaltrials:NCT00154193]Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients [clinicaltrials:NCT00154206]Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF) [clinicaltrials:NCT00154232]A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients. [clinicaltrials:NCT00154245]clinicaltrials:NCT00154284clinicaltrials:NCT00154310Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients. [clinicaltrials:NCT00170794]Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen [clinicaltrials:NCT00170820]Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients [clinicaltrials:NCT00170833]clinicaltrials:NCT00170846Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients [clinicaltrials:NCT00170859]Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients [clinicaltrials:NCT00170885]Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant [clinicaltrials:NCT00171379]Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus [clinicaltrials:NCT00171392]Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). [clinicaltrials:NCT00171418]The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS) [clinicaltrials:NCT00171431]The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia. [clinicaltrials:NCT00171457]The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn. [clinicaltrials:NCT00171470]Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). [clinicaltrials:NCT00171483]Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients [clinicaltrials:NCT00171496]Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients [clinicaltrials:NCT00171509]Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant [clinicaltrials:NCT00171717]Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients [clinicaltrials:NCT00171743]
overall official [clinicaltrials_vocabulary:overall-official]
Novartis [clinicaltrials_resource:7cb942c6d0724183a592d4221f454201]
Bio2RDF identifier
7cb942c6d0724183a592d4221f454201
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7cb942c6d0724183a592d4221f454201
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
trialandresults.registries@novartis.com
last name [clinicaltrials_vocabulary:last-name]
phone [clinicaltrials_vocabulary:phone]
862 778-8300
862-778-8300
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:7cb942c6d0724183a592d4221f454201
title
Novartis
@en
type
label
Novartis [clinicaltrials_resource:7cb942c6d0724183a592d4221f454201]
@en